Form: 8-K

Current report filing

January 24, 2019

Exhibit 99.1

 

LOGO

 

For investors    For media
Amy Wakeham    Jayme Rubenstein
+1 858-836-5000    +1 858-836-6798
investorrelations@resmed.com    news@resmed.com

ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2019

 

  •  

Year-over-year growth in revenue, gross margin, and operating profit

 

  •  

Well-positioned for future growth through further penetration of untreated sleep apnea and expanding portfolio in respiratory care and software as a service

Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. EST today at http://investor.resmed.com

SAN DIEGO, January 24, 2019 – ResMed Inc. (NYSE: RMD, ASX: RMD), a world-leading connected health company, today announced results for its quarter ended December 31, 2018.

Second Quarter 2019 Highlights

 

  •  

Revenue increased 8% to $651.1 million; up 9% on a constant currency basis

 

  •  

Gross Margin expanded 70bps to 58.9%

 

  •  

Net operating profit increased 8%; non-GAAP operating profit up 15%

 

  •  

GAAP diluted earnings per share of $0.86; non-GAAP diluted earnings per share of $1.00

“We had a solid quarter with top-line growth and gross margin expansion, as well as continued fiscal discipline to drive leverage and improved operating profit”, said Mick Farrell, ResMed’s CEO. “Our new AirFit F30 and AirFit N30i masks have been launched in many markets, and mask sales are growing well globally. During the quarter we further expanded our software and device ecosystems, through the acquisitions of MatrixCare and Propeller Health, to provide digital health solutions to millions more people worldwide. We are empowering people to live healthier and happier lives where they live, and we are doing this by providing innovative software, services, and solutions to improve outcomes, create efficiencies, and reduce overall healthcare system costs.”


RMD Second Quarter 2019 Earnings Press Release – Jan. 24, 2019    Page 2 of 9

 

Financial Results and Operating Metrics

Unaudited; $ in millions, except for per share amounts

 

     Three Months Ended  
     December 31,
2018
    December 31,
2017
    % Change     Constant
Currency (A)
 

Revenue

   $ 651.1     $ 601.3       8     9

Gross margin

     58.9     58.2     1    

Selling, general and administrative expenses

     161.6       151.8       6       8  

Research and development expenses

     43.1       40.6       6       9  

Income from operations

     157.1       146.0       8    

Non-GAAP income from operations

     181.1       157.3       15    

Net income

     124.6       9.5       1,208    

Non-GAAP net income

     144.5       143.8       0    

Diluted earnings per share

   $ 0.86     $ 0.07       1,129    

Non-GAAP diluted earnings per share

   $ 1.00     $ 1.00       —      
     Six Months Ended  
     December 31,
2018
    December 31,
2017
    % Change     Constant
Currency (A)
 

Revenue

   $ 1,239.4     $ 1,124.9       10     11

Gross margin

     58.6     58.3     1    

Selling, general and administrative expenses

     308.9       295.7       4       6  

Research and development expenses

     81.9       78.1       5       9  

Income from operations

     301.2       258.6       16    

Non-GAAP income from operations

     338.1       281.7       20    

Net income

     230.4       95.7       141    

Non-GAAP net income

     260.7       238.0       10    

Diluted earnings per share

   $ 1.60     $ 0.67       139    

Non-GAAP diluted earnings per share

   $ 1.81     $ 1.66       9    

 

(A)

In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency basis”, which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

Discussion of Second Quarter Results

 

  •  

Revenue in the U.S., Canada, and Latin America, excluding Software as a Service, grew by 9 percent compared to the prior year period, driven by strong sales across our mask and device product portfolios.

 

  •  

Revenue in combined Europe, Asia and other markets grew by 1 percent on a constant currency basis compared to the same period of the prior year. Mask sales were strong across these markets. As expected, device sales in France and Japan were impacted as customers completed their connected device upgrade programs. Device sales outside France and Japan grew well.

 

  •  

Software as a Service revenue increased by 63 percent, compared to the prior year period, due to continued growth in our Brightree service offerings and incremental contribution from the acquisition of MatrixCare, which closed in the second quarter and HEALTHCAREfirst, which closed in the first quarter.

 

  •  

Gross margin expanded by 70 basis points over the prior year period, primarily due to benefits from manufacturing and procurement efficiencies, product mix changes and higher margin contribution from MatrixCare, partially offset by declines in average selling prices.


RMD Second Quarter 2019 Earnings Press Release – Jan. 24, 2019    Page 3 of 9

 

  •  

Selling, general and administrative expenses increased by 6 percent compared to the prior year period, or by 8 percent on a constant currency basis. Excluding the impact of recent acquisitions, selling, general and administrative expenses increased by 4 percent on a constant currency basis. SG&A expenses improved to 24.8 percent of revenue in the quarter, compared with 25.2 percent in the same period of the prior year.

 

  •  

Income from operations increased by 8 percent and non-GAAP income from operations increased by 15 percent compared to the prior year period.

 

  •  

Net income increased by 1,208 percent, predominantly attributable to the one-time transition tax recognized in the prior year quarter, and non-GAAP net income remained stable compared to the prior year period. Non-GAAP measures adjust for amortization of acquired intangibles, MatrixCare deferred revenue, acquisition-related expenses, and the impact of U.S. tax reform.

 

  •  

GAAP diluted earnings per share increased by 1,129 percent, predominantly attributable to the one-time transition tax recognized in the prior year quarter, and non-GAAP diluted earnings per share remained stable compared with the same period of the prior year.

 

  •  

Cash flow from operations for the quarter was $129.5 million, compared to net income in the current quarter of $124.6 million. During the quarter we paid $52.8 million in dividends.

Other Business and Operational Highlights

 

  •  

Completed the acquisition of MatrixCare, a leader in software solutions for more than 15,000 providers across skilled nursing, life plan communities, senior living and private duty, for consideration of $750.0 million.

 

  •  

Commenced the previously announced joint venture with Verily, combining ResMed’s expertise in sleep apnea and Verily’s advanced health data analytics technologies, to study the health and financial impacts of undiagnosed and untreated sleep apnea, and to develop software solutions that enable healthcare providers to more efficiently identify, diagnose, treat and manage individuals with sleep apnea and other breathing-related sleep disorders.

 

  •  

Announced the acquisition of Propeller Health, a digital therapeutics company providing connected health solutions for people living with chronic obstructive pulmonary disease (COPD) and asthma, for $225.0 million. The transaction closed on January 7, 2019.

 

  •  

Through Brightree, acquired Apacheta Corporation, a cloud-based software as a service provider offering mobile applications that empower companies to automate and streamline processes in route sales, field marketing, pick-up and delivery, transportation, and field services.

 

  •  

Named one of America’s top 100 corporate citizens for the third straight year by Forbes and JUST Capital. ResMed ranked #18 out of 890 large publicly traded U.S. companies, and #1 out of 32 “Health Care Equipment & Services” companies.

Share repurchase program

We have temporarily suspended our repurchase program due to recent acquisitions. Accordingly, we did not repurchase any shares during the three months ended December 31, 2018.

Dividend program

The ResMed board of directors today declared a quarterly cash dividend of $0.37 per share. The dividend will have a record date of February 7, 2019, payable on March 14, 2019. The dividend will be paid in U.S. currency to holders of ResMed’s common stock trading on the New York Stock Exchange. Holders of Chess Depositary Instruments trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be February 6, 2019 for common stockholders and for CDI holders. ResMed has received a waiver from the ASX’s settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from February 6, 2019 through February 7, 2019, inclusive.


RMD Second Quarter 2019 Earnings Press Release – Jan. 24, 2019    Page 4 of 9

 

Webcast details

ResMed will discuss its second quarter fiscal year 2019 results on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on ResMed’s Investor Relations website at investor.resmed.com. Please go to this section of the website and click on the icon for the “Q2 2019 Earnings Webcast” to register and listen to the live webcast. A replay of the earnings webcast will be accessible on our website and available approximately two hours after the live webcast. In addition, a telephone replay of the conference call will be available approximately two hours after the webcast by dialing +1 800-585-8367 (U.S.) or +1 416-621-4642 (outside U.S.), and entering the passcode 6179558. The telephone replay will be available until February 7, 2019.

About ResMed

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our cloud-connected medical devices transform care for people with sleep apnea, COPD and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries. To learn more, visit ResMed.com and follow @ResMed.

Safe harbor statement

Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding ResMed’s projections of future revenue or earnings, expenses, new product development, new product launches, new markets for its products, the integration of acquisitions, litigation, and tax outlook – are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed’s periodic reports on file with the U.S. Securities & Exchange Commission. ResMed does not undertake to update its forward-looking statements.

– More –


RMD Second Quarter 2019 Earnings Press Release – Jan. 24, 2019    Page 5 of 9

 

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Income

(Unaudited; $ in thousands, except for per share amounts)

 

     Three Months Ended     Six Months Ended  
     December 31,
2018
    December 31,
2017
    December 31,
2018
    December 31,
2017
 

Net revenue

   $ 651,100     $ 601,273     $ 1,239,380     $ 1,124,932  

Cost of sales

     267,369       251,481       512,556       469,535  
  

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit

   $ 383,731     $ 349,792     $ 726,824     $ 655,397  

Operating expenses:

        

Selling, general and administrative

     161,579       151,816       308,881       295,666  

Research and development

     43,111       40,643       81,902       78,058  

Amortization of acquired intangible assets (1)

     15,840       11,317       28,707       23,099  

Acquisition related expenses (1)

     6,123       —         6,123       —    
  

 

 

   

 

 

   

 

 

   

 

 

 

Total operating expenses

   $ 226,653     $ 203,776     $ 425,613     $ 396,823  

Income from operations (1)

     157,078       146,016       301,211       258,574  

Other income (expenses), net:

        

Interest income (expense), net

   $ (6,809   $ (2,791   $ (9,595   $ (5,706

Other, net

     (621     (1,460     (3,086     (2,618
  

 

 

   

 

 

   

 

 

   

 

 

 

Total other income (expenses), net

     (7,430     (4,251     (12,681     (8,324
  

 

 

   

 

 

   

 

 

   

 

 

 

Income before income taxes

   $ 149,648     $ 141,765     $ 288,530     $ 250,250  

Income taxes

     21,634       132,238       54,778       154,599  

Loss attributable to equity method investments

     3,375       —         3,375       —    
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income

   $ 124,639     $ 9,527     $ 230,377     $ 95,651  
  

 

 

   

 

 

   

 

 

   

 

 

 

Basic earnings per share

   $ 0.87     $ 0.07     $ 1.61     $ 0.67  

Diluted earnings per share

   $ 0.86     $ 0.07     $ 1.60     $ 0.67  

Non-GAAP diluted earnings per share (1)

   $ 1.00     $ 1.00     $ 1.81     $ 1.66  

Basic shares outstanding

     142,923       142,715       142,796       142,511  

Diluted shares outstanding

     144,349       143,855       144,418       143,757  

 

(1)

See the reconciliation of non-GAAP financial measures in the table at the end of the press release.

– More –


RMD Second Quarter 2019 Earnings Press Release – Jan. 24, 2019    Page 6 of 9

 

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(Unaudited; $ in thousands)

 

     December 31,
2018
    June 30,
2018
 

ASSETS

    

Current assets:

    

Cash and cash equivalents

   $ 149,468     $ 188,701  

Accounts receivable, net

     477,191       483,681  

Inventories

     296,511       268,701  

Prepayments and other current assets

     140,369       124,634  
  

 

 

   

 

 

 

Total current assets

   $ 1,063,539     $ 1,065,717  

Non-current assets:

    

Property, plant and equipment, net

   $ 381,505     $ 386,550  

Goodwill and other intangibles, net

     2,243,971       1,284,128  

Deferred income taxes and other non-current assets

     170,801       327,528  
  

 

 

   

 

 

 

Total non-current assets

   $ 2,796,277     $ 1,998,206  
  

 

 

   

 

 

 

Total assets

   $ 3,859,816     $ 3,063,923  
  

 

 

   

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY:

    

Current liabilities:

    

Accounts payable

   $ 110,335     $ 92,723  

Accrued expenses

     191,564       185,805  

Deferred revenue

     72,685       60,828  

Income taxes payable

     49,881       160,427  

Short-term debt

     11,978       11,466  
  

 

 

   

 

 

 

Total current liabilities

   $ 436,443     $ 511,249  

Non-current liabilities:

    

Deferred revenue

   $ 76,773     $ 71,596  

Deferred income taxes

     79,057       13,084  

Other long term liabilities

     —         924  

Long-term debt

     1,185,500       269,988  

Long-term income taxes payable

     125,999       138,102  
  

 

 

   

 

 

 

Total non-current liabilities

   $ 1,467,329     $ 493,694  
  

 

 

   

 

 

 

Total liabilities

   $ 1,903,772     $ 1,004,943  
  

 

 

   

 

 

 

STOCKHOLDERS’ EQUITY:

    

Common stock

   $ 573     $ 571  

Additional paid-in capital

     1,460,705       1,450,821  

Retained earnings

     2,368,339       2,432,328  

Treasury stock

     (1,623,256     (1,600,412

Accumulated other comprehensive income

     (250,317     (224,328
  

 

 

   

 

 

 

Total stockholders’ equity

   $ 1,956,044     $ 2,058,980  
  

 

 

   

 

 

 

Total liabilities and stockholders’ equity

   $ 3,859,816     $ 3,063,923  
  

 

 

   

 

 

 

– More –


RMD Second Quarter 2019 Earnings Press Release – Jan. 24, 2019    Page 7 of 9

 

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(Unaudited; $ in thousands)

 

     Six Months Ended  
     December 31,
2018
    December 31,
2017
 

Cash flows from operating activities:

    

Net income

   $ 230,377     $ 95,651  

Adjustment to reconcile net income to cash provided by operating activities:

    

Depreciation and amortization

     66,453       58,945  

Loss attributable to equity method investments

     3,375       —    

Stock-based compensation costs

     25,011       23,958  

Impairment of equity investments

     2,959       2,254  

Changes in fair value of business combination contingent consideration

     (272     —    

Changes in operating assets and liabilities, net of effect of acquisitions:

    

Accounts receivable, net

     32,366       (26,145

Inventories, net

     (30,570     (20,760

Prepaid expenses, net deferred income taxes and other current assets

     (26,922     (2,858

Accounts payable, accrued expenses and other

     (125,190     95,489  
  

 

 

   

 

 

 

Net cash provided by operating activities

   $ 177,587     $ 226,534  

Cash flows from investing activities:

    

Purchases of property, plant and equipment

     (31,425     (32,000

Patent registration costs

     (4,643     (4,624

Business acquisitions, net of cash acquired

     (739,249     —    

Purchases of cost-method investments

     (2,967     (3,725

Purchases of equity-method investments

     (25,000     —    

Proceeds / (Payments) on maturity of foreign currency contracts

     (3,127     (3,330
  

 

 

   

 

 

 

Net cash used in investing activities

   $ (806,411   $ (43,679

Cash flows from financing activities:

    

Proceeds from issuance of common stock, net

     12,784       20,440  

Taxes paid related to net share settlement of equity awards

     (27,340     (13,853

Purchases of treasury stock

     (22,844     (8,541

Payment of business combination contingent consideration

     (430     —    

Proceeds from borrowings, net of borrowing costs

     1,091,230       50,000  

Repayment of borrowings

     (352,798     (110,000

Dividends paid

     (105,567     (99,553
  

 

 

   

 

 

 

Net cash (used in) / provided by financing activities

   $ 595,035     $ (161,507
  

 

 

   

 

 

 

Effect of exchange rate changes on cash

   $ (5,444   $ 15,616  
  

 

 

   

 

 

 

Net increase / (decrease) in cash and cash equivalents

     (39,233     36,964  

Cash and cash equivalents at beginning of period

     188,701       821,935  
  

 

 

   

 

 

 

Cash and cash equivalents at end of period

   $ 149,468     $ 858,899  
  

 

 

   

 

 

 

– More –


RMD Second Quarter 2019 Earnings Press Release – Jan. 24, 2019    Page 8 of 9

 

RESMED INC. AND SUBSIDIARIES

Reconciliation of Non-GAAP Financial Measures

(Unaudited; $ in thousands, except for per share amounts)

The measure, “non-GAAP income from operations” is reconciled with GAAP income from operations below:

 

     Three Months Ended      Six Months Ended  
     December 31,
2018
     December 31,
2017
     December 31,
2018
     December 31,
2017
 

GAAP income from operations

   $ 157,078    $ 146,016    $ 301,211    $ 258,574

Amortization of acquired intangible assets (A)

     15,840      11,317      28,707      23,099

Deferred revenue fair value adjustment (A)

     2,029      —          2,029      —    

Acquisition related expenses (A)

     6,123      —          6,123      —    
  

 

 

    

 

 

    

 

 

    

 

 

 

Non-GAAP income from operations

   $ 181,070    $ 157,333    $ 338,070    $ 281,673
  

 

 

    

 

 

    

 

 

    

 

 

 

The measures “non-GAAP net income” and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:

 

     Three Months Ended      Six Months Ended  
     December 31,
2018
     December 31,
2017
     December 31,
2018
     December 31,
2017
 

GAAP net income

   $ 124,639    $ 9,527    $ 230,377    $ 95,651

Amortization of acquired intangible assets, net of tax (A)

     12,271      7,697      22,258      15,710

Deferred revenue fair value adjustment (A)

     1,554      —          1,554      —    

Acquisition related expenses (A)

     5,362      —          5,362      —    

U.S. tax reform transition impact (A)

     644      119,880      1,178      119,880

U.S. tax reform impact on deferred taxes (A)

     —          6,723      —          6,723
  

 

 

    

 

 

    

 

 

    

 

 

 

Non-GAAP net income (A)

   $ 144,470    $ 143,827    $ 260,729    $ 237,964
  

 

 

    

 

 

    

 

 

    

 

 

 

Diluted shares outstanding

     144,349      143,855      144,418      143,757

GAAP diluted earnings per share

   $ 0.86    $ 0.07    $ 1.60    $ 0.67

Non-GAAP diluted earnings per share (A)

   $ 1.00    $ 1.00    $ 1.81    $ 1.66

 

(A)

ResMed adjusts for the impact of the amortization of acquired intangibles, deferred revenue fair value adjustment, acquisition-related expenses, and the impact of U.S. tax reform on income tax expense from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance.

ResMed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight when evaluating ResMed’s performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.

– More –


RMD Second Quarter 2019 Earnings Press Release – Jan. 24, 2019    Page 9 of 9

 

RESMED INC. AND SUBSIDIARIES

Revenue by Product and Region

(Unaudited; $ in thousands, except for per share amounts)

 

     Three Months Ended  
     December 31,
2018
     December 31,
2017
     % Change     Constant
Currency (A)
 

U.S., Canada and Latin America

          

Devices

   $ 186.5    $ 173.7      7  

Masks

     172.0      155.5      11  
  

 

 

    

 

 

    

 

 

   

Total Sleep and Respiratory Care

   $ 358.5    $ 329.2      9  

Software as a Service

     63.2      38.7      63  
  

 

 

    

 

 

    

 

 

   

Total

   $ 421.7    $ 367.9      15  
  

 

 

    

 

 

    

 

 

   

Combined Europe, Asia and other markets

          

Devices

   $ 156.2    $ 163.3      -4     -2

Masks

     73.2      70.1      4     8
  

 

 

    

 

 

    

 

 

   

 

 

 

Total Sleep and Respiratory Care

   $ 229.4    $ 233.4      -2       1

Global revenue

          

Devices

   $ 342.7    $ 337.0      2     3

Masks

     245.2      225.6      9     10
  

 

 

    

 

 

    

 

 

   

 

 

 

Total Sleep and Respiratory Care

   $ 587.9    $ 562.6      4     6

Software as a Service

     63.2      38.7      63     63
  

 

 

    

 

 

    

 

 

   

 

 

 

Total

   $ 651.1    $ 601.3      8     9
  

 

 

    

 

 

    

 

 

   

 

 

 
     Six Months Ended  
     December 31,
2018
     December 31,
2017
     % Change     Constant
Currency
Growth (A)
 

U.S., Canada and Latin America

          

Devices

   $ 358.9    $ 331.6      8  

Masks

     326.1      294.2      11  
  

 

 

    

 

 

    

 

 

   

Total Sleep and Respiratory Care

   $ 685.0    $ 625.8      9  

Software as a Service

     110.7      76.8      44  
  

 

 

    

 

 

    

 

 

   

Total

   $ 795.7    $ 702.6      13  
  

 

 

    

 

 

    

 

 

   

Combined Europe, Asia and other markets

          

Devices

   $ 307.9    $ 291.6      6     8

Masks

     135.8      130.7      4     7
  

 

 

    

 

 

    

 

 

   

 

 

 

Total Sleep and Respiratory Care

   $ 443.7    $ 422.3      5     8

Global revenue

          

Devices

   $ 666.8    $ 623.2      7     8

Masks

     461.9      424.9      9     10
  

 

 

    

 

 

    

 

 

   

 

 

 

Total Sleep and Respiratory Care

   $ 1,128.7    $ 1,048.1      8     9

Software as a Service

     110.7      76.8      44     44
  

 

 

    

 

 

    

 

 

   

 

 

 

Total

   $ 1,239.4    $ 1,124.9      10     11
  

 

 

    

 

 

    

 

 

   

 

 

 

 

(A)

In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency basis”, which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

– End –